中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
13期
14-16
,共3页
脑梗塞%血栓溶解疗法%组织型纤溶酶原激活物%血压
腦梗塞%血栓溶解療法%組織型纖溶酶原激活物%血壓
뇌경새%혈전용해요법%조직형섬용매원격활물%혈압
Brain infarction%Thrombolytic therapy%Tissue plasminogen activator%Blood pressure
目的 探讨急性脑梗死应用阿替普酶静脉溶栓治疗后90d预后的相关危险因素.方法 选择40例行阿替普酶静脉溶栓治疗的急性脑梗死患者,根据90 d时改良Rankin量表评分(mRS评分),将患者分为预后良好组(mRS评分0～1分)和预后不良组(mRS评分2～6分),对两组患者危险因素进行比较.结果 预后良好组18例,预后不良组22例.预后不良组与预后良好组相比,年龄[(64.64±11.30)岁比(58.94±10.47)岁]、发病至治疗时间[(376.73±316.32)min比(176.00±59.74) min]、溶栓前国立卫生研究院卒中量表(NIHSS)评分[(16.73±8.46)分比(11.22±5.20)分]、溶栓治疗24 h内最大收缩压(SBPmax)[(186.59±24.79)mm Hg(1 mm Hg=0.133 kPa)比(169.00±23.04)mm Hg]、收缩压连续变异性(SBPV)[(17.11±3.90)mm Hg比(13.33±4.97) mm Hg]差异有统计学意义(P＜0.05).结论 年龄、发病至治疗时间、溶栓前NIHSS评分、溶栓治疗24h内的SBPmax、SBPV与急性脑梗死阿替普酶静脉溶栓治疗后90d预后相关.
目的 探討急性腦梗死應用阿替普酶靜脈溶栓治療後90d預後的相關危險因素.方法 選擇40例行阿替普酶靜脈溶栓治療的急性腦梗死患者,根據90 d時改良Rankin量錶評分(mRS評分),將患者分為預後良好組(mRS評分0～1分)和預後不良組(mRS評分2～6分),對兩組患者危險因素進行比較.結果 預後良好組18例,預後不良組22例.預後不良組與預後良好組相比,年齡[(64.64±11.30)歲比(58.94±10.47)歲]、髮病至治療時間[(376.73±316.32)min比(176.00±59.74) min]、溶栓前國立衛生研究院卒中量錶(NIHSS)評分[(16.73±8.46)分比(11.22±5.20)分]、溶栓治療24 h內最大收縮壓(SBPmax)[(186.59±24.79)mm Hg(1 mm Hg=0.133 kPa)比(169.00±23.04)mm Hg]、收縮壓連續變異性(SBPV)[(17.11±3.90)mm Hg比(13.33±4.97) mm Hg]差異有統計學意義(P＜0.05).結論 年齡、髮病至治療時間、溶栓前NIHSS評分、溶栓治療24h內的SBPmax、SBPV與急性腦梗死阿替普酶靜脈溶栓治療後90d預後相關.
목적 탐토급성뇌경사응용아체보매정맥용전치료후90d예후적상관위험인소.방법 선택40례행아체보매정맥용전치료적급성뇌경사환자,근거90 d시개량Rankin량표평분(mRS평분),장환자분위예후량호조(mRS평분0～1분)화예후불량조(mRS평분2～6분),대량조환자위험인소진행비교.결과 예후량호조18례,예후불량조22례.예후불량조여예후량호조상비,년령[(64.64±11.30)세비(58.94±10.47)세]、발병지치료시간[(376.73±316.32)min비(176.00±59.74) min]、용전전국립위생연구원졸중량표(NIHSS)평분[(16.73±8.46)분비(11.22±5.20)분]、용전치료24 h내최대수축압(SBPmax)[(186.59±24.79)mm Hg(1 mm Hg=0.133 kPa)비(169.00±23.04)mm Hg]、수축압련속변이성(SBPV)[(17.11±3.90)mm Hg비(13.33±4.97) mm Hg]차이유통계학의의(P＜0.05).결론 년령、발병지치료시간、용전전NIHSS평분、용전치료24h내적SBPmax、SBPV여급성뇌경사아체보매정맥용전치료후90d예후상관.
Objective To investigate the risk factors related with the prognosis of patients with acute cerebral infarction after intravenous thrombolysis by alteplase in 90 days.Methods Forty patients with acute cerebral infarction treated by intravenous thrombolysis with aheplase were selected and assigned into good outcome group [modified Rankin scale (mRS) 0-1 score] and poor outcome group (mRS 2-6 scores) according to mRS at 90 days.The risk factors were compared between two groups.Results Poor outcome group (22 cases) comparing with good outcome group (18 cases),the values of age [ (64.64±11.30) years vs.(58.94±10.47) years ],onset to therapy time(OTT) [(376.73±316.32)min vs.( 176.00±59.74) min],National Institutes of Health stroke scale (NIHSS) score before thrombolysis [ ( 16.73±8.46)scores vs. (11.22±5.20) scores],maximum of systolic blood pressure (SBPmax) in the first 24 hours after thrombolysis[ ( 186.59±24.79 )mm Hg ( 1 mm Hg =0.133 kPa) vs.( 169.00±23.04) mm Hg] and systolic blood pressure variability (SBPV)[(17.11±3.90) mm Hg vs.(13.33±4.97) mm Hg] had significant differences (P＜ 0.05).Conclusion The values ofage,OTT,NIHSS score before thrombolysis,SBPmax and SBPV in the first 24 hours after thrombolysis are related with the prognosis of patients with acute cerebral infarction after intravenous thrombolysis by altcplase in 90 days.
